Rein Therapeutics, Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stock holder Matters and Issuer Purchases of Equity Securities Our common stock trades under the symbol “RNTX” on the Nasdaq Capital Market and had been publicly traded since June 29, 2017. Prior to this time, there was no public market for our common stock. Holders of Our Common Stock As of March 24, 2026, there were approximately 117 holders of record of shares of our common stock. This number does not include stockholders for whom shares are held in “nominee” or “street” name. Dividend Policy We have never declared nor paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future. Any future determination to pay cash dividends will be made at the discretion of our board of directors and will depend on restrictions and other factors our board of directors may deem relevant. Investors should not purchase our common stock with the expectation of receiving cash dividends. Recent Sales of Unregistered Securities In April 2025, certain institutional investors, including Bios Equity Partners, LP, or Bios Partners, exercised warrants for the purchase of 1,049,638 share of our common stock for the gross proceeds of $1.7 million and exchanged outstanding warrants for pre-funded warrants and the cash purchase price of an aggregate of $3.1 million. All shares of common stock and warrants were issued pursuant to Section 4(a)(2) of the Securities Act, as transactions not involving a public offering. For more information, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations–Overview and Recent Developments–April 2025 Warrant Transactions and Private Placement.” During the year ended December 31, 2025, we sold 2,727,162 shares of our common stock to Yorkville, in satisfaction of an aggregate of $3.0 million of principal and accrued interest owed by us to Yorkville under our Pre-Paid Advance Agreement dated July 29, 2025. All shares of common stock issued and sold to Yorkville were issued pursuant to Section 4(a)(2) of the Securities Act, as transactions not involving a public offering. Purchases of Equity Securities by the Issuer and Affiliated Purchasers None. Equity Compensation Plan Information Information about our equity compensation plans will be included in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders and is incorporated herein by reference. Item 6. Reserved 83